News

Evaluate Alzheimer’s digital biomarker in partnership with vTv Therapeutics

January 6, 2020

MONTREAL, CANADA — Perceiv AI has started a project in partnership with vTv Therapeutics LLC (NASDAQ:VTVT) to evaluate their prognostic digital biomarkers technology. The goal is to improve clinical trials in Alzheimer’s disease by selecting individuals at a higher risk of cognitive decline.

PERCEIV AI WIN CENTECH PROPULSION PROGRAM AND OPEN NEW OFFICES

September 1, 2019

MONTREAL, CANADA — Perceiv AI is proud to announce that they have been selected to be part of the Propulsion two-year program from the CENTECH accelerator. Perceiv AI will receive $25K in grant and move to their new offices in downtown Montreal at 400 Montfort street.

ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2019

July 14, 2019

LOS ANGELES, USA — Perceiv AI Chief Executive Officer, Dr. Christian Dansereau, present results at AAIC 2019 - "PRE-SCREENING MACHINE LEARNING MODEL FOR β-AMYLOID POSITIVE ENRICHMENT". Results can be found in The Journal of the Alzheimer's Association, Vol. 15, Issue 7, P414–P415. https://doi.org/10.1016/j.jalz.2019.06.1011

CTAD Alzheimer congress - 11TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE

October 25, 2018

BARCELONA, SPAIN — Dr. Christian Dansereau, Chief Executive Officer, speaks at CTAD 2018 - "IDENTIFYING RISK OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT FOR POPULATION ENRICHMENT OF CLINICAL TRIALS".
https://dx.doi.org/10.14283/jpad.2018.39